Table 3.
Summary of Findings
| Outcome | During Treatment | Post-Treatment | Combined | |||
|---|---|---|---|---|---|---|
| n Significant |
n NS |
n Significant |
n NS |
n Significant |
n NS |
|
| Quality of Life | 5 | 1 | 3 | 2 | 2 | 1 |
| Physical – Self-Reported | ||||||
| Fatigue | 5 | 3 | 7 | 3 | 0 | 4 |
| Pain | 1 | 0 | 2 | 1 | NA | |
| Sleep | 2 | 2 | 4 | 2 | 2 | 1 |
| Othera | 2 | 2 | 9 | 0 | 0 | 1 |
| Physical – Objective | ||||||
| Physical Fitness | NA | 1 | 4 | NA | ||
| Actigraphy | 1 | 0 | 1 | 0 | NA | |
| Biomarkers | 4 | 0 | 3 | 2 | NA | |
| Psychological/Cognitive | ||||||
| Anxiety | 4 | 4 | 0 | 1 | 1 | 1 |
| Depression | 3 | 4 | 2 | 3 | 2 | 1 |
| Distress | 2 | 0 | NA | 0 | 1 | |
| Perceived Stress | 3 | 0 | 1 | 3 | NA | |
| Otherb | 3 | 1 | 1 | 0 | 0 | 2 |
| Cognition | NA | 2 | 1 | NA | ||
Note. Table summarizes between-group main effects. n=number of studies; NA=not applicable (outcome not included).
a
Includes general symptoms (intensity/frequency), prostate symptoms, nausea/vomiting, dyspnea, menopausal symptoms, lymphedema, and vigor/vitality.
b
Includes benefit-finding, intrusive/avoidant thoughts, life satisfaction, mindfulness, spirituality, and affect.